bevacizumab,panitumumab
roche,igm biosciences,amgen,takeda
['biomarker', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'igm bio']
dr. yamazuki elaborating on the importance of upfront detailed ngs at diagnosis of mcrc based on the paradigm biomarker study #asco2023 #asco23 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.